2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 Post author:alarpharm Post published:13 . 5 . 2022 Post category:Media releases You Might Also Like 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020 2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual Property Administration, Application No. 201780055635.3 21 . 11 . 2022
